Literature DB >> 10946422

Hepatitis C kinetics: mathematical modeling of viral response to therapy.

T J Layden1, B Mika, T E Wiley.   

Abstract

Mathematical models have been used to study the dynamics of HIV. Using these same principles, the dynamics of hepatitis C virus (HCV) are reviewed during interferon (IFN) therapy. After initiating IFN treatment, there is an IFN dose-dependent exponential decline in viral RNA levels within the first 48 hours. This rapid 1.0 to 2.0 log decline was best explained by an effect of IFN in inhibiting viral production with a varying degree of effectiveness. By applying mathematical principles, viral serum half-life was estimated to be 3.0 hours and viral production rat was calculated to be 1.0 x 10(12) virions per day. After this rapid first-phase decline there was a slower second phase decline in viral levels that was highly variable between subjects. This phase was dependent on the rate of elimination of HCV-infected liver cells. The rapidity of the second phase proved to be the best predictor of early viral clearance. The use of these models to understand the life cycle of viruses and their response to therapy is reviewed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946422     DOI: 10.1055/s-2000-9940

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  7 in total

Review 1.  Cytopathic bovine viral diarrhea viruses (BVDV): emerging pestiviruses doomed to extinction.

Authors:  Ernst Peterhans; Claudia Bachofen; Hanspeter Stalder; Matthias Schweizer
Journal:  Vet Res       Date:  2010-03-04       Impact factor: 3.683

2.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.

Authors:  Isabelle Desombere; Hans Van Vlierberghe; Sibyl Couvent; Filip Clinckspoor; Geert Leroux-Roels
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

4.  Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Authors:  Golo Ahlenstiel; Birgit Edlich; Leah J Hogdal; Yaron Rotman; Mazen Noureddin; Jordan J Feld; Lauren E Holz; Rachel H Titerence; T Jake Liang; Barbara Rehermann
Journal:  Gastroenterology       Date:  2011-07-07       Impact factor: 22.682

5.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Authors:  David Butera; Svetlana Marukian; Amy E Iwamaye; Edgardo Hembrador; Thomas J Chambers; Adrian M Di Bisceglie; Edgar D Charles; Andrew H Talal; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

6.  Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature.

Authors:  Chon Saeng Kim; Sun Ju Keum; Sung Key Jang
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

7.  CD100 up-regulation induced by interferon-α on B cells is related to hepatitis C virus infection.

Authors:  Yu He; Yonghong Guo; Yun Zhou; Ying Zhang; Chao Fan; Guangxi Ji; Yu Wang; Zhiyuan Ma; Jianqi Lian; Chunqiu Hao; Zhi Q Yao; Zhansheng Jia
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.